【摘要】 目的:比较各大洲、不同人类发展指数(human development index, HDI)国家2022年甲状腺癌流行现状，了解中国与高HDI国家和东亚地区甲状腺癌发病和死亡差异，为中国甲状腺癌诊断策略的制定提供依据。方法:从GLOBOCAN 2022数据库下载并整理甲状腺癌发病和死亡数据，使用Spearman秩相关系数分析HDI与标化发病率(standardized incidence rate, SIR)、标化死亡率(standardized mortality rate, SMR)、死亡发病比(mortality to incidence ratio, M/I)之间的关联。结果:2022年全球各大洲甲状腺癌SIR以非洲、欧洲、拉丁美洲和加勒比地区、大洋洲、亚洲和北美洲的顺序递增，SMR以北美洲、欧洲、亚洲、大洋洲、拉丁美洲和加勒比地区和非洲的顺序递增。甲状腺癌SIR(r=0.693,P<0.001)与HDI呈正相关，而SMR(r=-0.264,P<0.001)和M/I(r=-0.711,P<0.001)与HDI呈负相关。中国甲状腺癌SIR高于东亚地区，SMR与东亚地区相等。中国甲状腺癌SIR高于高HDI国家，SMR低于高HDI国家。结论:甲状腺癌过度诊断问题在中国等人类高发展指数国家较为严重，中国应及时调整甲状腺癌诊断和筛查策略，避免医疗资源浪费。更多还原

【Abstract】 Objective: To compare the current status of thyroid cancer prevalence in continents and countries with different human development indexes(HDI) in 2022, investigate the differences in thyroid cancer incidence and mortality between China and high HDI countries/East Asia, in order to provide a basis for the development of diagnosis strategies for thyroid cancer in China. Methods: Data of thyroid cancer incidence and mortality were downloaded and compiled from the GLOBOCAN 2022 database, and the relations of HDI to standardized incidence rate(SIR), standardized mortality rate(SMR), and mortality to incidence ratio(M/I) were analyzed using the Spearman rank correlation coefficient. Results: The ascending order of SIR of thyroid cancer in continents in 2022 were Africa, Europe, Latin America and the Caribbean, Oceania, Asia, and North America, and that of SMR were North America, Europe, Asia, Oceania, Latin America and the Caribbean and Africa. SIR of thyroid cancer(r=0.693, P<0.001) was positively correlated to HDI, while SMR(r=-0.264, P<0.001) and M/I(r=-0.711, P<0.001) were negatively correlated to HDI. The SIR of thyroid cancer in China was higher than that in East Asia, and the SMR was equal to that in East Asia. SIR of thyroid cancer in China was higher than that in high HDI countries, and SMR was lower than that in high HDI countries. Conclusion: The overdiagnosis of thyroid cancer is relatively serious in countries with high HDI, such as China. The diagnosis and screening strategies of thyroid cancer should be adjusted in time in China to avoid the waste of medical resources.更多还原